Navigation path

Pharmaceuticals - Community Register


Community register of veterinary medicinal products


Product information

Invented name: Nobivac Myxo-RHD   
Auth. number : EU/2/11/132
Active substance : Live myxoma vectored RHD virus strain 009
ATC: Anatomical main group: QI - Immunologicals
Therapeutic subgroup: QI08 - Immunologicals for leporidae
Pharmacological subgroup: QI08A - Rabbit
Chemical subgroup: QI08AD - Live viral vaccines
Chemical substance: QI08AD - Live viral vaccines
(See WHO ATCvet Index)
Indication: For active immunisation of rabbits from 5 weeks of age onwards to reduce mortality and clinical signs of myxomatosis and to prevent mortality due to rabbit haemorrhagic disease caused by classical RHD virus strains.
Marketing Authorisation Holder: Intervet International B.V.
Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
9/09/2011 Centralised - Authorisation EMEA/V/C/2004 (2011)6421 of 7/09/2011
14/02/2014 Centralised - Variation EMEA/V/C/2004/IB/2
Updated with Decision(2015)1302 of 19/02/2015
23/02/2015 Centralised - Yearly update (2015)1302 of 19/02/2015
30/03/2015 Centralised - 2-Monthly update EMEA/V/C/2004/IB/4 (2015)2248 of 26/03/2015
23/06/2016 Centralised - Renewal EMEA/V/C/2004/R/5 (2016)3961 of 21/06/2016
5/08/2016 Centralised - Variation EMEA/V/C/2004/IAIN/6
Updated with Decision(2017)6278 of 14/09/2017
18/09/2017 Centralised - Yearly update (2017)6278 of 14/09/2017